Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Treatments by Mechanism

Top 12 mechanisms across 104 industry trials with a known mechanism of action.

See full pipeline →

CD20-directed Cytolytic Antibody

31 trials 11 active 2 sponsors

Kinase Inhibitor

3 trials 2 active 2 sponsors

Interferon beta

12 trials 1 active 5 sponsors

Nicotinic acid receptor/Nrf2

25 trials 2 sponsors

Integrin Receptor Antagonist

11 trials 1 sponsor

Pyrimidine Synthesis Inhibitor

9 trials 3 sponsors

Sphingosine 1-phosphate Receptor Modulator

4 trials 2 sponsors

Purine Antimetabolite

4 trials 2 sponsors

CD52-directed Cytolytic Antibody

2 trials 2 sponsors

Muscarinic receptor

1 trials 1 sponsor

Benzodiazepine

1 trials 1 sponsor

Acetylcholine Release Inhibitor

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Clinical Pipeline by Phase

476 industry-sponsored trials across 117 sponsors

View full landscape →

Showing 91 of 91 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Roche	Ocrelizumab	CD20-directed Cytolytic Antibody [EPC]	RECRUITING	2027-03-12	NCT07483450
Novartis	Fingolimod	—	RECRUITING	2027-09-30	NCT04480853
Novartis	—	—	RECRUITING	2028-11-30	NCT06733922
Novartis	Ofatumumab	CD20-directed Cytolytic Antibody [EPC]	ACTIVE NOT RECRUITING	2027-04-13	NCT05090371
Bristol-Myers Squibb	BMS-986374	—	ACTIVE NOT RECRUITING	2028-12-29	NCT06396039
Novartis	Ofatunumab	—	ACTIVE NOT RECRUITING	2026-05-18	NCT06444113
Qilu Pharmaceutical (Hainan) Co., Ltd.	Dimethyl Fumarate Enteric-coated Capsules	—	NOT YET RECRUITING	2028-04	NCT07138833
Biogen	Dimethyl fumarate	Nicotinic acid receptor/Nrf2	COMPLETED	2025-03-27	NCT05658484
Novartis	Fingolimod 0.5mg	—	COMPLETED	2025-03-25	NCT04667949
Novartis	Ofatumumab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2025-02-13	NCT05199571
Novartis	Ofatumumab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2025-02-04	NCT05084638
Roche	Ocrelizumab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2024-04-08	NCT04998812
Roche	Ocrelizumab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2024-03-29	NCT04998851
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany	Mavenclad®	—	COMPLETED	2023-09-21	NCT04783935
Novartis	Quadrivalent influenza vaccine	—	COMPLETED	2023-07-06	NCT04667117
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany	Mavenclad®	—	COMPLETED	2023-06-20	NCT04776213
Roche	Ocrelizumab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2022-12-15	NCT04377555
Sanofi	TERIFLUNOMIDE HMR1726	—	COMPLETED	2022-05-13	NCT03856619
Novartis	Ofatumumab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2022-05-10	NCT04869358
Merck KGaA, Darmstadt, Germany	Mavenclad®	—	COMPLETED	2021-11-12	NCT03369665
Novartis	BAF312	—	COMPLETED	2021-09-06	NCT04792567
Sanofi	TERIFLUNOMIDE	Pyrimidine Synthesis Inhibitor [EPC]	COMPLETED	2021-07-12	NCT04410965
EMD Serono Research & Development Institute, Inc.	—	—	COMPLETED	2021-02-27	NCT03961204
Roche	Ocrelizumab 300 mg	—	COMPLETED	2021-02-15	NCT03589105
Biogen	peginterferon beta-1a	Interferon beta [EPC]	COMPLETED	2020-10-26	NCT03177083
Genzyme, a Sanofi Company	alemtuzumab GZ402673	—	COMPLETED	2020-07-15	NCT02255656
Merck KGaA, Darmstadt, Germany	Mavenclad®	—	COMPLETED	2020-05-05	NCT03364036
Novartis	Fingolimod	—	COMPLETED	2020-01-24	NCT02232061
Genzyme, a Sanofi Company	—	—	COMPLETED	2019-12-11	NCT03784898
Novartis	Fingolimod	—	COMPLETED	2019-03-05	NCT03257358
Novartis	Fingolimod	—	COMPLETED	2019-02-18	NCT01705236
Bayer	—	—	COMPLETED	2018-05-24	NCT03269175
Biogen	—	—	COMPLETED	2018-01-27	NCT03091569
Biogen	peginterferon beta-1a	Interferon beta [EPC]	COMPLETED	2017-10-02	NCT02587065
Biogen	dimethyl fumarate	Nicotinic acid receptor/Nrf2	COMPLETED	2017-06-12	NCT02471560
Biogen	dimethyl fumarate	Nicotinic acid receptor/Nrf2	COMPLETED	2017-02-16	NCT02410278
Novartis	Fingolimod 0.5 mg	—	COMPLETED	2017-01-18	NCT02373098
Teva Branded Pharmaceutical Products R&D, Inc.	Copaxone®	—	COMPLETED	2017-01-10	NCT02499900
Novartis	FTY720	—	COMPLETED	2016-12-12	NCT01585298
Novartis	fingolimod	—	COMPLETED	2016-11-14	NCT02720107
Merck KGaA, Darmstadt, Germany	Rebif	Interferon beta [EPC]	COMPLETED	2016-08-20	NCT02254304
Merck KGaA, Darmstadt, Germany	Rebif®	—	COMPLETED	2016-04-30	NCT02064816
Genzyme, a Sanofi Company	Alemtuzumab GZ402673	—	COMPLETED	2016-04	NCT02205489
Biogen	dimethyl fumarate	Nicotinic acid receptor/Nrf2	COMPLETED	2016-03-31	NCT01930708
Merck KGaA, Darmstadt, Germany	Rebif®	—	COMPLETED	2016-02-29	NCT01791244
Biogen	dimethyl fumarate	Nicotinic acid receptor/Nrf2	COMPLETED	2016-02	NCT02125604
EMD Serono	—	—	COMPLETED	2016-01	NCT02019550
Novartis	Fingolimod (FTY720)	—	COMPLETED	2015-12-26	NCT01498887
Novartis	—	—	COMPLETED	2015-12	NCT02307838
Sanofi	Teriflunomide	Pyrimidine Synthesis Inhibitor [EPC]	COMPLETED	2015-11	NCT01895335
Novartis	Fingolimod	—	COMPLETED	2015-09	NCT01333501
Novartis	Fingolimod	—	COMPLETED	2015-07-13	NCT01623596
Novartis	Fingolimod	—	COMPLETED	2015-04	NCT01578330
AbbVie	—	—	COMPLETED	2015-03	NCT01930799
Biogen	dimethyl fumarate	Nicotinic acid receptor/Nrf2	COMPLETED	2015-02	NCT02090413
Novartis	Fingolimod	—	COMPLETED	2014-06	NCT01317004
Bayer	—	—	COMPLETED	2014-04	NCT01795872
Biogen	BG00002	—	COMPLETED	2013-12	NCT02142205
Biogen	BG00012 (DMF)	—	COMPLETED	2013-11	NCT01873417
Biogen	Fampridine	—	COMPLETED	2013-07	NCT01480076
Novartis	fingolimod	—	COMPLETED	2013-06	NCT01420055
Novartis	Fingolimod	—	COMPLETED	2013-06	NCT01534182
Jazz Pharmaceuticals	Sativex	—	COMPLETED	2013-05	NCT01964547
Novartis	Fingolimod	—	COMPLETED	2012-08	NCT01216072
Biogen	BG00002 (natalizumab)	—	COMPLETED	2012-07	NCT00871780
Novartis	Fingolimod	—	COMPLETED	2012-07	NCT01310166
EMD Serono	Rebif	Interferon beta [EPC]	COMPLETED	2012-02-29	NCT01085318
Biogen	—	—	COMPLETED	2011-10	NCT01556685
Astellas Pharma Inc	Solifenacin Succinate	Muscarinic receptor	COMPLETED	2011-01-28	NCT00629642
EMD Serono	—	—	COMPLETED	2010-11	NCT01034579
Biogen	BG00002 (natalizumab)	—	COMPLETED	2009-11	NCT00536120
Biogen	Natalizumab	Integrin Receptor Antagonist [EPC]	COMPLETED	2008-12	NCT00744679
Biogen	Natalizumab	Integrin Receptor Antagonist [EPC]	TERMINATED	2023-10-09	NCT05532163
Novartis	Ofatumumab	CD20-directed Cytolytic Antibody [EPC]	TERMINATED	2023-04-14	NCT04878211
Mallinckrodt ARD LLC	Acthar Gel	—	TERMINATED	2020-07-14	NCT03126760
Biogen	natalizumab	Integrin Receptor Antagonist [EPC]	TERMINATED	2016-05-18	NCT02342704
Biogen	natalizumab	Integrin Receptor Antagonist [EPC]	TERMINATED	2016-05-02	NCT02241785
Biogen	dimethyl fumarate	Nicotinic acid receptor/Nrf2	TERMINATED	2016-04-15	NCT02343159
EMD Serono	Rebif®	—	TERMINATED	2015-04	NCT02117050
Novartis	—	—	TERMINATED	2014-07	NCT01490840
Novartis	Venlafaxine	—	TERMINATED	2013-09	NCT01436643
Novartis	Rivastigmine transdermal patch	—	TERMINATED	2011-01	NCT00881205
Bayer	Interferon beta-1b, FRP within 15 days after randomization	—	TERMINATED	2009-09	NCT00780455
Roche	Ocrelizumab	CD20-directed Cytolytic Antibody [EPC]	WITHDRAWN	2025-01-31	NCT05208840
Biogen	dimethyl fumarate	Nicotinic acid receptor/Nrf2	WITHDRAWN	2019-07	NCT02472938
Biogen	dimethyl fumarate	Nicotinic acid receptor/Nrf2	WITHDRAWN	2017-10	NCT02090348
Biogen	Interferon Beta	—	WITHDRAWN	2017-02	NCT02234869
Biogen	peginterferon beta-1a	Interferon beta [EPC]	WITHDRAWN	2016-08	NCT02568111
Novartis	Fingolimod	—	WITHDRAWN	2014-06	NCT01621269
Novartis	—	—	WITHDRAWN	2013-07	NCT01709812
Biogen	TYSABRI and AVONEX	—	WITHDRAWN	2009-08-01	NCT00771043

Showing 100 of 171 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Novartis	CYB704	—	RECRUITING	2026-10-14	NCT06847724
Amgen	Ocrelizumab (US)	—	RECRUITING	2027-01-15	NCT06700343
Celltrion	CT-P53	—	RECRUITING	2027-02	NCT05906992
Sanofi	Frexalimab	—	RECRUITING	2027-07-15	NCT07325292
TG Therapeutics, Inc.	Ublituximab	—	RECRUITING	2027-12-01	NCT05877963
Biocad	BCD-281	—	RECRUITING	2028-12	NCT07321093
Novartis	Remibrutinib oral treatment	—	RECRUITING	2029-07-20	NCT06846281
Roche	Ocrelizumab	CD20-directed Cytolytic Antibody [EPC]	RECRUITING	2029-12-31	NCT06675955
Zenas BioPharma (USA), LLC	Orelabrutinib	—	RECRUITING	2030-06	NCT07299019
Zenas BioPharma (USA), LLC	Orelabrutinib	—	RECRUITING	2030-06	NCT07067463
Novartis	Remibrutinib (blinded)	—	RECRUITING	2030-12-03	NCT07225504
Bristol-Myers Squibb	Ozanimod	—	RECRUITING	2031-04-11	NCT06408259
Roche	Ocrelizumab	CD20-directed Cytolytic Antibody [EPC]	ACTIVE NOT RECRUITING	2026-10-22	NCT03523858
TG Therapeutics, Inc.	Ublituximab	—	ACTIVE NOT RECRUITING	2026-10-31	NCT07211633
Immunic AG	IMU-838 tablets	—	ACTIVE NOT RECRUITING	2026-11	NCT05134441
Immunic AG	IMU-838 tablets	—	ACTIVE NOT RECRUITING	2026-11	NCT05201638
Sanofi	Frexalimab	—	ACTIVE NOT RECRUITING	2027-05-06	NCT06141473
Biogen	BIIB017 (peginterferon beta-1a)	—	ACTIVE NOT RECRUITING	2027-05-20	NCT03958877
Roche	Ocrelizumab	CD20-directed Cytolytic Antibody [EPC]	ACTIVE NOT RECRUITING	2027-12-31	NCT05269004
Sanofi	Frexalimab	—	ACTIVE NOT RECRUITING	2028-03-24	NCT06141486
Novartis	Ofatumumab	CD20-directed Cytolytic Antibody [EPC]	ACTIVE NOT RECRUITING	2028-09-30	NCT03650114
Sanofi	Tolebrutinib	—	ACTIVE NOT RECRUITING	2029-04-30	NCT06372145
TG Therapeutics, Inc.	Ublituximab	—	ACTIVE NOT RECRUITING	2032-05-31	NCT04130997
Novartis	Remibrutinib	Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2026-04-30	NCT05156281
Novartis	Remibrutinib	Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2026-04-30	NCT05147220
Novartis	Fingolimod	—	ACTIVE NOT RECRUITING	2026-03-25	NCT04926818
Novartis	Ofatumumab approved dose	—	ACTIVE NOT RECRUITING	2026-01-28	NCT06869785
Roche	Fenebrutinib	—	ACTIVE NOT RECRUITING	2026-01-27	NCT04586010
Roche	Fenebrutinib	—	ACTIVE NOT RECRUITING	2025-09-17	NCT04544449
Roche	Fenebrutinib	—	ACTIVE NOT RECRUITING	2025-09-05	NCT04586023
Roche	Ocrelizumab	CD20-directed Cytolytic Antibody [EPC]	ACTIVE NOT RECRUITING	2025-06-30	NCT04548999
Roche	Ocrelizumab	CD20-directed Cytolytic Antibody [EPC]	ACTIVE NOT RECRUITING	2025-06-09	NCT05123703
Roche	Ocrelizumab	CD20-directed Cytolytic Antibody [EPC]	ACTIVE NOT RECRUITING	2025-01-15	NCT04035005
Roche	Ocrelizumab	CD20-directed Cytolytic Antibody [EPC]	ACTIVE NOT RECRUITING	2024-12-19	NCT04544436
Supernus Pharmaceuticals, Inc.	Phase 2; Low Dose MYOBLOC	—	ACTIVE NOT RECRUITING	2023-07-01	NCT04815967
Novartis	Interferon beta-1a	Interferon beta [EPC]	ACTIVE NOT RECRUITING	2017-07-14	NCT01892722
TG Therapeutics, Inc.	Ublituximab	—	NOT YET RECRUITING	2030-01-01	NCT07220252
Biogen	Diroximel Fumarate	Nicotinic acid receptor/Nrf2	NOT YET RECRUITING	2034-07-28	NCT07483632
Sanofi	Tolebrutinib	—	COMPLETED	2025-11-14	NCT04458051
Novartis	Ofatumumab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2025-11-04	NCT04788615
Roche	Ocrelizumab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2025-07-17	NCT03599245
Biogen	dimethyl fumarate	Nicotinic acid receptor/Nrf2	COMPLETED	2025-07-08	NCT02283853
Novartis	Ofatumumab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2024-10-09	NCT04353492
Biogen	Diroximel fumarate	Nicotinic acid receptor/Nrf2	COMPLETED	2024-09-11	NCT05083923
Sanofi	Tolebrutinib	—	COMPLETED	2024-08-29	NCT04411641
Sanofi	Tolebrutinib	—	COMPLETED	2024-07-16	NCT04410991
Sanofi	Tolebrutinib	—	COMPLETED	2024-07-15	NCT04410978
Biocad	Divozilimab	—	COMPLETED	2024-05-16	NCT06987851
Actelion	Ponesimod	Sphingosine 1-phosphate Receptor Modulator [EPC]	COMPLETED	2024-01-16	NCT03232073
Novartis	Ofatumumab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2023-11-20	NCT04486716
Bristol-Myers Squibb	Tetanus, diphtheria, and acellular pertussis vaccine	—	COMPLETED	2023-11-15	NCT05028634
Mapi Pharma Ltd.	GA Depot	—	COMPLETED	2023-06-13	NCT04121221
Clene Nanomedicine	CNM-Au8	—	COMPLETED	2023-05-29	NCT04626921
Roche	Ocrelizumab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2023-04-11	NCT02688985
Roche	Ocrelizumab IV	—	COMPLETED	2023-03-10	NCT05232825
Biogen	Natalizumab	Integrin Receptor Antagonist [EPC]	COMPLETED	2023-01-31	NCT03689972
Bristol-Myers Squibb	RPC1063	—	COMPLETED	2023-01-05	NCT02576717
Biocad	BCD-132	—	COMPLETED	2022-09-09	NCT05385744
Novartis	Siponimod	Sphingosine 1-phosphate Receptor Modulator [EPC]	COMPLETED	2022-07-06	NCT03623243
Jazz Pharmaceuticals	Nabiximols	—	COMPLETED	2022-05-04	NCT04657666
Cinnagen	Pegylated interferon beta-1a	—	COMPLETED	2022-04-27	NCT05242133
Polpharma Biologics S.A.	Intravenous (IV) infusions	—	COMPLETED	2021-08-23	NCT04115488
Biogen	ALKS 8700	—	COMPLETED	2021-06-01	NCT02634307
Bionorica SE	BX-1	—	COMPLETED	2021-03-30	NCT03756974
Adamas Pharmaceuticals, Inc.	ADS-5102, 274 mg	—	COMPLETED	2020-11-17	NCT03567057
Cinnagen	Ocrelizumab (CinnaGen, Iran)	—	COMPLETED	2020-11-09	NCT04966338
TG Therapeutics, Inc.	Ublituximab	—	COMPLETED	2020-08-04	NCT03277248
TG Therapeutics, Inc.	Ublituximab	—	COMPLETED	2020-07-23	NCT03277261
RVL Pharmaceuticals, Inc.	Arbaclofen	—	COMPLETED	2020-01-27	NCT03319732
Adamas Pharmaceuticals, Inc.	ADS-5102, 137 mg	—	COMPLETED	2019-12-10	NCT03436199
Biogen	dimethyl fumarate	Nicotinic acid receptor/Nrf2	COMPLETED	2019-11-08	NCT00835770
Genzyme, a Sanofi Company	Teriflunomide	Pyrimidine Synthesis Inhibitor [EPC]	COMPLETED	2019-10-25	NCT02201108
Roche	Ocrelizumab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2019-10-25	NCT02861014
AB Science	Masitinib	—	COMPLETED	2019-09	NCT01433497
Novartis	Ofatumumab subcutaneous injection	—	COMPLETED	2019-07-05	NCT02792218
Biogen	ALKS 8700	—	COMPLETED	2019-06-27	NCT03093324
Roche	Ocrelizumab Dose 1	—	COMPLETED	2019-05-31	NCT03606460
Actelion	ponesimod	Sphingosine 1-phosphate Receptor Modulator [EPC]	COMPLETED	2019-05-16	NCT02425644
Roche	Ocrelizumab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2019-05-03	NCT02637856
RVL Pharmaceuticals, Inc.	Arbaclofen	—	COMPLETED	2018-12-03	NCT03290131
Biocad	BCD-054 180 mcg	—	COMPLETED	2018-11-23	NCT02744222
Novartis	Fingolimod	—	COMPLETED	2018-10-19	NCT01201356
Biogen	dimethyl fumarate	Nicotinic acid receptor/Nrf2	COMPLETED	2018-09-24	NCT02555215
Biogen	dimethyl fumarate	Nicotinic acid receptor/Nrf2	COMPLETED	2017-04-24	NCT02525874
Bristol-Myers Squibb	Ozanimod	—	COMPLETED	2017-03-27	NCT02047734
Roche	23-PPV	—	COMPLETED	2017-02-14	NCT02545868
Bristol-Myers Squibb	Ozanimod	—	COMPLETED	2016-12-22	NCT02294058
Biogen	dimethyl fumarate	Nicotinic acid receptor/Nrf2	COMPLETED	2016-12-21	NCT02579681
Biocad	BCD-033 (interferon beta 1a)	—	COMPLETED	2016-11-21	NCT02727907
Novartis	BAF312	—	COMPLETED	2016-04-29	NCT01665144
Genzyme, a Sanofi Company	alemtuzumab	CD52-directed Cytolytic Antibody [EPC]	COMPLETED	2016-02	NCT00930553
Biogen	fampridine	—	COMPLETED	2016-02	NCT02219932
Biogen	Midazolam	Benzodiazepine [EPC]	COMPLETED	2016-01	NCT01462318
Biocad	BCD-063	—	COMPLETED	2015-11	NCT02753088
Biogen	BIIB041 (fampridine)	—	COMPLETED	2015-10	NCT01917019
Biogen	BIIB017	—	COMPLETED	2015-10	NCT01939002
Biogen	peginterferon beta-1a	Interferon beta [EPC]	COMPLETED	2015-10	NCT01332019
Roche	Ocrelizumab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2015-07-23	NCT01194570
Biogen	dimethyl fumarate	Nicotinic acid receptor/Nrf2	COMPLETED	2015-06-16	NCT01838668
Roche	Interferon beta-1a	Interferon beta [EPC]	COMPLETED	2015-05-12	NCT01412333

Showing 100 of 130 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Vidya Therapeutics Inc	VT7208	—	RECRUITING	2026-10-30	NCT07085507
Roche	Ocrelizumab Test Formulation	—	RECRUITING	2027-01-31	NCT07074886
Bristol-Myers Squibb	BMS-986368	—	RECRUITING	2027-05-26	NCT06782490
Roche	Fenebrutinib	—	RECRUITING	2027-06-08	NCT07161258
Roche	RO7268489	—	RECRUITING	2028-05-30	NCT07282574
Tr1X, Inc.	TRX319	—	RECRUITING	2028-08	NCT07477639
Ever Supreme Bio Technology Co., Ltd.	Allogeneic umbilical cord mesenchymal stem cells	—	RECRUITING	2028-10-31	NCT05532943
ModernaTX, Inc.	mRNA-1195	—	RECRUITING	2029-01-08	NCT06735248
Novartis	rapcabtagene autoleucel (YTB323)	—	RECRUITING	2030-06-14	NCT06675864
Miltenyi Biomedicine GmbH	MB-CART2019.1	—	RECRUITING	2030-08-16	NCT07178431
Novartis	rapcabtagene autoleucel (YTB323)	—	RECRUITING	2030-10-01	NCT06617793
Tiziana Life Sciences LTD	Foralumab TZLS-401 100 µg	—	RECRUITING	2026-04-30	NCT06890923
Ashvattha Therapeutics, Inc.	18F-OP-801	—	RECRUITING	2026-01-01	NCT05395624
Tiziana Life Sciences LTD	Foralumab	—	RECRUITING	2025-11	NCT06292923
Hope Biosciences Research Foundation	Autologous HB-adMSCs	—	ACTIVE NOT RECRUITING	2027-01	NCT06800404
Kyverna Therapeutics	KYV-101	—	ACTIVE NOT RECRUITING	2027-04	NCT06384976
Eli Lilly	LY3541860	—	ACTIVE NOT RECRUITING	2025-10-18	NCT06220669
Zenas BioPharma (USA), LLC	Obexelimab	—	ACTIVE NOT RECRUITING	2025-08-28	NCT06564311
Roche	Ocrelizumab	CD20-directed Cytolytic Antibody [EPC]	ACTIVE NOT RECRUITING	2023-10-05	NCT04075266
Roche	Fenebrutinib	—	ACTIVE NOT RECRUITING	2023-03-29	NCT05119569
Sanofi	SAR441344 IV	—	ACTIVE NOT RECRUITING	2022-09-21	NCT04879628
Immunic AG	IMU-838 (30 mg/day)	—	ACTIVE NOT RECRUITING	2020-04-24	NCT03846219
TG Therapeutics, Inc.	Ublituximab	—	NOT YET RECRUITING	2027-07-31	NCT07503873
NeuroGenesis Ltd.	NG01 - Autologous bone marrow derived human stromal cells	—	NOT YET RECRUITING	2027-10-01	NCT06961383
Cabaletta Bio	CABA-201	—	NOT YET RECRUITING	2028-09	NCT07006805
Roche	Ocrelizumab co-formulated with rHuPH20	—	NOT YET RECRUITING	2029-08-01	NCT07503340
Biogen	BIIB091	—	COMPLETED	2026-02-10	NCT05798520
Reveal Pharmaceuticals Inc.	RVP-001	—	COMPLETED	2025-12-19	NCT06322342
Contineum Therapeutics	PIPE-307 Dose A	—	COMPLETED	2025-07-14	NCT06083753
Clene Nanomedicine	gold nanocrystals	—	COMPLETED	2025-05-27	NCT03993171
Sanofi	Tolebrutinib	—	COMPLETED	2024-11-26	NCT03996291
Hope Biosciences Research Foundation	HB-adMSCs	—	COMPLETED	2024-06-04	NCT05116540
Actelion	Ponesimod 10 mg	—	COMPLETED	2023-09-06	NCT01093326
TG Therapeutics, Inc.	Ublituximab	—	COMPLETED	2022-11-11	NCT03381170
GeNeuro Innovation SAS	temelimab 18 mg/kg	—	COMPLETED	2022-01-24	NCT04480307
AbbVie	elezanumab	—	COMPLETED	2021-08-09	NCT03737851
Brainstorm-Cell Therapeutics	NurOwn (MSC-NTF cells)	—	COMPLETED	2021-03-11	NCT03799718
AbbVie	elezanumab	—	COMPLETED	2021-01-15	NCT03737812
Biocad	BCD-132, 125 mg	—	COMPLETED	2020-07-13	NCT04056897
Sanofi	SAR442168	—	COMPLETED	2020-01-02	NCT03889639
Novartis	Ofatumumab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2019-12-26	NCT03249714
Novartis	—	—	COMPLETED	2019-08-26	NCT03560739
Canbex Therapeutics Ltd	VSN16R	—	COMPLETED	2017-10	NCT02542787
TG Therapeutics, Inc.	Ublituximab	—	COMPLETED	2017-09-27	NCT02738775
GeNeuro SA	GNbAC1	—	COMPLETED	2017-08	NCT02782858
Teva Branded Pharmaceutical Products R&D, Inc.	Laquinimod	—	COMPLETED	2017-05-04	NCT02284568
Mapi Pharma Ltd.	GA Depot 80 mg	—	COMPLETED	2017-05	NCT02212886
MediciNova	ibudilast	—	COMPLETED	2017-05	NCT01982942
Innate Immunotherapeutics	MIS416	—	COMPLETED	2017-05	NCT02228213
InteKrin Therapeutics, Inc.	INT131	—	COMPLETED	2016-12-12	NCT02638038
Novartis	BAF312	—	COMPLETED	2016-10-10	NCT01185821
Opexa Therapeutics, Inc.	Tcelna	—	COMPLETED	2016-10	NCT01684761
Biogen	dimethyl fumarate	Nicotinic acid receptor/Nrf2	COMPLETED	2016-09-23	NCT02410200
Biogen	BIIB019 (Daclizumab)	—	COMPLETED	2016-08-25	NCT01051349
Adamas Pharmaceuticals, Inc.	ADS-5102	—	COMPLETED	2016-06	NCT02471222
Biogen	dimethyl fumarate	Nicotinic acid receptor/Nrf2	COMPLETED	2016-05-02	NCT02097849
Merck KGaA, Darmstadt, Germany	ATX-MS-1467	—	COMPLETED	2016-04-30	NCT01973491
Merck KGaA, Darmstadt, Germany	IFN beta 1a 44 mcg TIW	—	COMPLETED	2016-03-31	NCT01514370
Translational Biosciences	Umbilical cord mesenchymal stem cells	—	COMPLETED	2016-03	NCT02034188
Tanabe Pharma Corporation	MT-1303-Low	—	COMPLETED	2016-03	NCT01890655
Biogen	BIIB033	—	COMPLETED	2015-12	NCT01864148
RedHill Biopharma Limited	RHB-104	—	COMPLETED	2015-12	NCT01717664
Merck KGaA, Darmstadt, Germany	VigantOL oil plus interferon beta-1a (Rebif)	—	COMPLETED	2015-04	NCT01285401
Merck KGaA, Darmstadt, Germany	Rebif	Interferon beta [EPC]	COMPLETED	2015-03	NCT01198132
Biogen	natalizumab	Integrin Receptor Antagonist [EPC]	COMPLETED	2014-12	NCT01416155
GSK	GSK239512	—	COMPLETED	2014-09	NCT01772199
Tanabe Pharma Corporation	MT-1303-Low	—	COMPLETED	2014-07	NCT01742052
Novartis	AIN457	—	COMPLETED	2014-06	NCT01433250
Delta Crystallon BV	recombinant human alpha B-crystallin	—	COMPLETED	2014-06	NCT02442570
GeNeuro Innovation SAS	GNbAC1	—	COMPLETED	2014-04	NCT01639300
Biogen	natalizumab IV	—	COMPLETED	2014-04	NCT01405820
MorphoSys AG	MOR103	—	COMPLETED	2014-01	NCT01517282
Neurotec Pharma	NT-KO-003	—	COMPLETED	2014-01	NCT01428726
Avanir Pharmaceuticals	AVP-923-45	—	COMPLETED	2013-09-26	NCT01324232
GSK	Ofatumumab 3mg	—	COMPLETED	2013-08-23	NCT01457924
Biogen	BIIB041 (PR Fampridine)	—	COMPLETED	2013-08	NCT01597297
Innate Immunotherapeutics	MIS416	—	COMPLETED	2012-06	NCT01191996
Biogen	BIIB019 (Daclizumab High Yield Process)	—	COMPLETED	2012-05	NCT00870740
Novartis	AIN457	—	COMPLETED	2012-04	NCT01051817
Novartis	Fingolimod	—	COMPLETED	2012-04	NCT00670449
Roche	Ocrelizumab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2012-03-09	NCT00676715
Biogen	dimethyl fumarate	Nicotinic acid receptor/Nrf2	COMPLETED	2012-03	NCT01156311
Sanofi	teriflunomide	Pyrimidine Synthesis Inhibitor [EPC]	COMPLETED	2012-01	NCT01403376
Ono Pharma USA Inc	ONO-4641	—	COMPLETED	2011-12	NCT01081782
Biogen	natalizumab	Integrin Receptor Antagonist [EPC]	COMPLETED	2011-11	NCT01071083
Actelion	ACT-128800 Dose 1	—	COMPLETED	2011-06-01	NCT01006265
Novartis	BAF312	—	COMPLETED	2011-05-04	NCT00879658
Biogen	BIIB019 (Daclizumab High Yield Process)	—	COMPLETED	2011-05	NCT00390221
Eli Lilly	LY2127399	—	COMPLETED	2011-02	NCT00882999
GSK	Ofatumumab 100	—	COMPLETED	2010-05	NCT00640328
Sanofi	Nerispirdine	—	COMPLETED	2010-03	NCT00811902
Impax Laboratories, LLC	IPX056	—	COMPLETED	2010-01	NCT00914290
Sanofi	Nerispirdine	—	COMPLETED	2009-06	NCT00772525
UCB Pharma	CDP323	—	COMPLETED	2009-03	NCT00726648
RemeGen Co., Ltd.	RC18 160mg	—	TERMINATED	2026-04-03	NCT04625153
Mapi Pharma Ltd.	GA Depot 40mg once monthly	—	TERMINATED	2025-06-20	NCT03362294
Sanofi	SAR443820	—	TERMINATED	2024-11-21	NCT05630547
Atara Biotherapeutics	ATA188	—	TERMINATED	2023-11-09	NCT03283826
GeNeuro Innovation SAS	Temelimab 18 mg/kg	—	TERMINATED	2022-05-18	NCT05049161
Clene Nanomedicine	CNM-Au8	—	TERMINATED	2022-04-27	NCT03536559

Showing 84 of 84 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Roche	RO7121932 IV	—	RECRUITING	2027-07-08	NCT05704361
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	CC-97540	—	RECRUITING	2027-07-15	NCT06220201
AstraZeneca	AZD0120 - Regimen 1	—	RECRUITING	2028-12-07	NCT07224373
Kite, A Gilead Company	KITE-363	—	RECRUITING	2029-06	NCT07304154
Autolus Limited	Obecabtagene autoleucel (obe-cel)	—	RECRUITING	2029-08-15	NCT07139743
Inventage Lab., Inc.	Vivitrol Injectable Product	—	RECRUITING	2025-12-30	NCT05620940
ImStem Biotechnology	IMS001	—	ACTIVE NOT RECRUITING	2027-12	NCT04956744
Roche	P-CD19CD20-ALLO1 Cells	—	ACTIVE NOT RECRUITING	2032-08-31	NCT07008378
Abata Therapeutics	ABA-101	—	ACTIVE NOT RECRUITING	2026-02	NCT06566261
R-Pharm	RPH-035	—	ACTIVE NOT RECRUITING	2026-01-12	NCT07597668
Cellerys AG	CLS12311 low	—	ACTIVE NOT RECRUITING	2025-12	NCT06430671
Contineum Therapeutics	PIPE-791	—	COMPLETED	2025-06-04	NCT06683612
Roche	Ocrelizumab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2025-06-03	NCT03972306
Motric Bio	MTR-601	—	COMPLETED	2024-10-16	NCT06117020
LAPIX Therapeutics Inc.	LPX-TI641	—	COMPLETED	2024-08-15	NCT05853835
Anokion SA	ANK-700	—	COMPLETED	2024-04-23	NCT04602390
Contineum Therapeutics	PIPE-791	—	COMPLETED	2024-02-01	NCT05983939
GSK	GSK3888130B	—	COMPLETED	2023-10-12	NCT05131971
Guangzhou Lupeng Pharmaceutical Company LTD.	LP-168 tablet	—	COMPLETED	2022-11-20	NCT05432713
Merck KGaA, Darmstadt, Germany	Cladribine	Purine Antimetabolite [EPC]	COMPLETED	2022-09-02	NCT03745144
Sanofi	Tolebrutinib	—	COMPLETED	2022-05-23	NCT06106074
Contineum Therapeutics	PIPE-307	—	COMPLETED	2021-11-10	NCT04941781
Sanofi	RIPK1 inhibitor	—	COMPLETED	2021-10-11	NCT04982991
Contineum Therapeutics	PIPE-307	—	COMPLETED	2021-09-01	NCT04725175
Banner Life Sciences LLC	Monomethyl Fumarate 190 Mg	—	COMPLETED	2021-08-27	NCT05181215
Sanofi	Tolebrutinib	—	COMPLETED	2020-07-08	NCT06064539
Sanofi	SAR442168	—	COMPLETED	2019-12-30	NCT04171310
Banner Life Sciences LLC	Bafiertam	Nicotinic acid receptor/Nrf2	COMPLETED	2019-10-19	NCT04022473
GeNeuro Australia PTY Ltd	GNbAC1	—	COMPLETED	2018-11-02	NCT03574428
Biocad	BCD-132	—	COMPLETED	2018-10-18	NCT03551275
Abide Therapeutics	ABX-1431 HCl	—	COMPLETED	2018-07-23	NCT03138421
Sanofi	GZ402668	—	COMPLETED	2018-05-16	NCT02977533
AbbVie	ABT-555	—	COMPLETED	2018-04-20	NCT02601885
Bristol-Myers Squibb	RPC1063	—	COMPLETED	2017-10-20	NCT02797015
Acorda Therapeutics	rHIgM22	—	COMPLETED	2017-09	NCT02398461
Banner Life Sciences LLC	monomethyl fumarate 190 mg	—	COMPLETED	2017-02-17	NCT04570670
Biogen	BIIB033 (opicinumab)	—	COMPLETED	2016-11	NCT02833142
Arrien Pharmaceuticals	ARN-6039	—	COMPLETED	2016-10-06	NCT03237832
Biogen	BIIB033	—	COMPLETED	2016-09	NCT02641041
GE Healthcare	Arm 1 - GEH120714 (18F) Injection	—	COMPLETED	2016-05	NCT01738347
Genzyme, a Sanofi Company	Acyclovir	Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC]	COMPLETED	2016-03	NCT02583594
Genzyme, a Sanofi Company	GZ402668	—	COMPLETED	2016-03	NCT02282826
Pfenex, Inc	Interferon beta-1b (PF530, Betaferon)	—	COMPLETED	2015-10	NCT02474134
Biogen	BIIB061	—	COMPLETED	2015-08	NCT02521545
Tanabe Pharma Corporation	MT-1303-FormA	—	COMPLETED	2015-03	NCT02310048
MedImmune LLC	MEDI-551 30 MG-IV	—	COMPLETED	2015-01-02	NCT01585766
Biogen	Study Drug	—	COMPLETED	2014-12	NCT02201849
Tanabe Pharma Corporation	MT-1303	—	COMPLETED	2014-12	NCT02293967
Biogen	peginterferon beta-1a	Interferon beta [EPC]	COMPLETED	2014-12	NCT02269930
Vaccinex Inc.	VX15/2503	—	COMPLETED	2014-11	NCT01764737
Acorda Therapeutics	rHIgM22	—	COMPLETED	2014-10	NCT01803867
Biogen	Natalizumab	Integrin Receptor Antagonist [EPC]	COMPLETED	2014-09	NCT01884935
Sanofi	Teriflunomide HMR1726	—	COMPLETED	2014-07	NCT02046629
Roche	olesoxime (TRO19622)	—	COMPLETED	2014-01	NCT01808885
Apitope Technology (Bristol) Ltd.	ATX-MS-1467	—	COMPLETED	2013-07	NCT01097668
GSK	GSK239512	—	COMPLETED	2013-04-15	NCT01802931
Biogen	—	—	COMPLETED	2012-10	NCT01610310
Biogen	BIIB033	—	COMPLETED	2012-04	NCT01244139
Biogen	Interferon beta-1a (current approved manufacturing process invloving FBS)	—	COMPLETED	2012-04	NCT01500408
GeNeuro Innovation SAS	GNbAC1	—	COMPLETED	2012-03	NCT01699555
GSK	Firategrast immediate release tablet	—	COMPLETED	2011-09-17	NCT01416363
GSK	GSK2018682	—	COMPLETED	2011-03-29	NCT01431937
GSK	GSK2018682 CD2 Capsule; GSK2018682 CD3 non-micronised Tablet; GSK2018682 CD3 micronised Tablet; GSK2018682 CD3 non-micronised Tablet in fed state	—	COMPLETED	2011-02-15	NCT01466322
GSK	GSK2018682	—	COMPLETED	2010-12-20	NCT01387217
Delta Crystallon BV	recombinant human alpha B-crystallin	—	COMPLETED	2010-10	NCT02442557
Daiichi Sankyo	CS-0777 tablets	—	COMPLETED	2010-09	NCT00616733
GSK	A	—	COMPLETED	2010-07-06	NCT01424462
Bayer	F-18 FEDAA1106 (BAY85-8101)	—	COMPLETED	2009-12	NCT01031199
Biogen	BG00012	—	COMPLETED	2009-10-31	NCT00837785
Merck KGaA, Darmstadt, Germany	Cladribine	Purine Antimetabolite [EPC]	COMPLETED	2009-01	NCT00938366
Bristol-Myers Squibb	11C-BMS-986196	—	TERMINATED	2023-12-18	NCT05064436
H. Lundbeck A/S	Lu AG06466	—	TERMINATED	2023-01-19	NCT04990219
American CryoStem Corporation	Autologous adipose derived mesenchymal cells	—	TERMINATED	2018-05-18	NCT02326935
AbbVie	ABT-555	—	TERMINATED	2015-12	NCT02606630
Pfizer	PF-06342674 0.25 mg/kg	—	TERMINATED	2015-10	NCT02045732
BBB-Therapeutics B.V.	2B3-201	—	TERMINATED	2015-01	NCT02048358
GSK	Part A: 100 mg/mL GSK2618960	—	TERMINATED	2013-08-06	NCT01808482
Elan Pharmaceuticals	ELND002	—	TERMINATED	2012-12	NCT01318421
Elan Pharmaceuticals	ELND002	—	TERMINATED	2012-12	NCT01144351
GSK	GSK1223249	—	TERMINATED	2012-01-23	NCT01435993
GSK	GSK1223249	—	TERMINATED	2010-08-26	NCT01424423
Indapta Therapeutics, INC.	IDP-023	—	SUSPENDED	2026-12-31	NCT06677710
Tiziana Life Sciences LTD	Intranasal Foralumab Solution	—	WITHDRAWN	2022-11	NCT05029609
Healeon Medical Inc	—	—	WITHDRAWN	2022-10	NCT02939859

Novel Drugs by Company (New molecular entities)

Biogen 2 drugs

PLEGRIDY

PEGINTERFERON BETA-1A

Sanofi 1 drug

BANNER LIFE SCIENCES 1 drug

Novartis 1 drug

Bayer 1 drug

QUESTCOR PHARMA 1 drug

H.P. ACTHAR GEL

REPOSITORY CORTICOTROPIN

SERONO INC 1 drug

CYCLE 1 drug

FINGOLIMOD LAURYL SULFATE

NDA 2021

Reformulations (7 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.